MedTrace Logo

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

NCT06435455 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2024-07-08

No results posted yet for this study

Summary

This s a multi-center, open-label phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patients with advanced or metastatic solid tumors harboring KRAS G12C mutation.

Conditions

  • Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation

Interventions

DRUG

GH21

GH21 Capsules, Oral Drug Specification: 3mg/capsule; 10mg/capsule

DRUG

D-1553

D-1553 Film-coated Tablets, Oral Drug Sepcification: 200mg/tablet

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    collaborator OTHER

  • Suzhou Genhouse Bio Co., Ltd.

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2027-09-30
Completion
2027-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06435455 on ClinicalTrials.gov